MX2010009351A - Particulas similares a virus cristalizadas con azucar. - Google Patents
Particulas similares a virus cristalizadas con azucar.Info
- Publication number
- MX2010009351A MX2010009351A MX2010009351A MX2010009351A MX2010009351A MX 2010009351 A MX2010009351 A MX 2010009351A MX 2010009351 A MX2010009351 A MX 2010009351A MX 2010009351 A MX2010009351 A MX 2010009351A MX 2010009351 A MX2010009351 A MX 2010009351A
- Authority
- MX
- Mexico
- Prior art keywords
- vlps
- virus
- particles
- sugar
- glassified
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16023—Virus like particles [VLP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención describe y reclama partículas similares a virus (VLPs) asociadas con cristal de azúcar para mejorar la estabilidad general de las VLPs. Estas formulaciones de VLPs reducirán el costo y aumentarán la distribución y entrega de vacunas basadas en VLP en todo el mundo. La invención también reclama métodos para preparar y suministrar dicha formulación a un paciente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3124308P | 2008-02-25 | 2008-02-25 | |
PCT/US2009/035122 WO2009108689A1 (en) | 2008-02-25 | 2009-02-25 | Sugar glassified virus like particles (vlps) |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010009351A true MX2010009351A (es) | 2011-03-04 |
Family
ID=41016454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010009351A MX2010009351A (es) | 2008-02-25 | 2009-02-25 | Particulas similares a virus cristalizadas con azucar. |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2254554A1 (es) |
JP (1) | JP2011514337A (es) |
CN (1) | CN102014873A (es) |
BR (1) | BRPI0908861A2 (es) |
CA (1) | CA2716546A1 (es) |
MX (1) | MX2010009351A (es) |
RU (1) | RU2010139478A (es) |
WO (1) | WO2009108689A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
DK2370099T3 (en) | 2008-12-09 | 2016-08-01 | Novavax Inc | Rsv f modified proteins and methods of their use |
JP6073031B2 (ja) * | 2009-12-28 | 2017-02-01 | タケダ ヴァクシーンズ, インコーポレイテッド | インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法 |
GB201002419D0 (en) * | 2010-02-12 | 2010-03-31 | Isis Innovation | Stable live vaccine formulations |
EA201390812A1 (ru) * | 2010-12-02 | 2013-11-29 | Онколитикс Байотек Инк. | Лиофилизированные вирусные составы |
CN103347535B (zh) | 2010-12-02 | 2015-11-25 | 昂科利蒂克斯生物科技公司 | 液体病毒制剂 |
EP2723371B1 (en) | 2011-06-24 | 2019-10-23 | Merck Sharp & Dohme Corp. | Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same |
SG10201602434UA (en) * | 2011-09-30 | 2016-05-30 | Novavax Inc | Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus |
US20130089638A1 (en) * | 2011-10-11 | 2013-04-11 | Mead Johnson Nutrition Company | Compositions Comprising Maltotriose And Methods Of Using Same To Inhibit Damage Caused By Dehydration Processes |
WO2015034924A1 (en) | 2013-09-03 | 2015-03-12 | Georgia Tech Research Corporation | Thermally stable vaccine formulations and microneedles |
SG10201808645TA (en) | 2013-12-16 | 2018-11-29 | Massachusetts Inst Technology | Fortified Micronutrient Salt Formulations |
WO2015095230A1 (en) * | 2013-12-16 | 2015-06-25 | Massachusetts Institute Of Technology | Micromolded or 3-d printed pulsatile release vaccine formulations |
EA201691348A1 (ru) * | 2013-12-31 | 2016-11-30 | Инфекшес Дизиз Рисерч Инститьют | Однофлаконные вакцинные составы |
US20170065707A1 (en) * | 2014-05-06 | 2017-03-09 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for thermally stable human papillomavirus formulations |
US11273127B2 (en) | 2014-05-06 | 2022-03-15 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for thermally stable multi-targeted antigens |
CN114617959A (zh) | 2015-09-03 | 2022-06-14 | 诺瓦瓦克斯股份有限公司 | 具有改进的稳定性和免疫原性的疫苗组合物 |
KR20200000497A (ko) * | 2015-09-04 | 2020-01-02 | 인벤트프라이즈 엘엘씨 | Vlp 안정화된 백신 조성물 |
US12083228B2 (en) | 2017-07-24 | 2024-09-10 | Novavax, Inc. | Methods and compositions for treating respiratory disease |
BR112020019108A2 (pt) | 2018-03-19 | 2020-12-29 | Novavax, Inc. | Vacinas polivalentes de nanopartículas de influenza |
EP3976092A1 (en) * | 2019-05-25 | 2022-04-06 | Infectious Disease Research Institute | Composition and method for spray drying an adjuvant vaccine emulsion |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6290991B1 (en) * | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
GB9705588D0 (en) * | 1997-03-18 | 1997-05-07 | Anglia Research Foundation | Stable particle in liquid formulations |
JP5475215B2 (ja) * | 2003-02-24 | 2014-04-16 | ファーマシューティカル プロダクションズ, インコーポレイテッド | 経粘膜薬物送達システム |
GB0409795D0 (en) * | 2004-04-30 | 2004-06-09 | Glaxosmithkline Biolog Sa | Drying method |
US7871632B2 (en) * | 2004-07-12 | 2011-01-18 | Adventrx Pharmaceuticals, Inc. | Compositions for delivering highly water soluble drugs |
GB0502661D0 (en) * | 2005-02-09 | 2005-03-16 | Stabilitech Ltd | A desiccated product |
MY139088A (en) * | 2005-02-21 | 2009-08-28 | Lg Life Sciences Ltd | Sustained release composition of protein drug |
-
2009
- 2009-02-25 CN CN2009801146099A patent/CN102014873A/zh active Pending
- 2009-02-25 RU RU2010139478/15A patent/RU2010139478A/ru not_active Application Discontinuation
- 2009-02-25 CA CA2716546A patent/CA2716546A1/en not_active Abandoned
- 2009-02-25 MX MX2010009351A patent/MX2010009351A/es unknown
- 2009-02-25 JP JP2010547860A patent/JP2011514337A/ja active Pending
- 2009-02-25 BR BRPI0908861A patent/BRPI0908861A2/pt not_active IP Right Cessation
- 2009-02-25 WO PCT/US2009/035122 patent/WO2009108689A1/en active Application Filing
- 2009-02-25 EP EP09713904A patent/EP2254554A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2009108689A1 (en) | 2009-09-03 |
RU2010139478A (ru) | 2012-05-20 |
CA2716546A1 (en) | 2009-09-03 |
CN102014873A (zh) | 2011-04-13 |
JP2011514337A (ja) | 2011-05-06 |
EP2254554A1 (en) | 2010-12-01 |
BRPI0908861A2 (pt) | 2018-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010009351A (es) | Particulas similares a virus cristalizadas con azucar. | |
MX354750B (es) | PARTÍCULAS PSEUDO-VIRALES (PPVs) QUE COMPRENDEN GLICOPROTEÍNAS DEL VIRUS DE LA RABIA. | |
WO2007130327A3 (en) | Influenza virus-like particle (vlp) compositions | |
MX342608B (es) | Particulas de suministro similares a viriones para moleculas de arn de autorreplicacion. | |
EA201190327A1 (ru) | Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv | |
GB201205632D0 (en) | Method and apparatus | |
IN2012DN02736A (es) | ||
WO2008011636A3 (en) | Targeted gene delivery for dendritic cell vaccination | |
WO2007130330A3 (en) | Polyvalent influenza virus-like particle (vlp) compositions | |
MX348823B (es) | Formulaciones estables de linaclotida. | |
WO2012047856A3 (en) | Novel inhibitors of secretion of hepatitis b virus antigens | |
WO2011027257A3 (en) | Pcsk9 vaccine | |
MX361139B (es) | Mutantes de virus de influenza y usos para los mismos. | |
MX2019012939A (es) | Formulaciones que contienen linaclotida para administracion oral. | |
WO2011086093A3 (en) | Pharmaceutical compositions for oral administration of insulin peptides | |
MX349119B (es) | Vacuna de virus de dengue inactivado. | |
MX2011007692A (es) | Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion. | |
WO2010149727A3 (en) | Injectable formulations containing asenapine and method of treatment using same | |
AU2011280259A8 (en) | Influenza vaccine | |
AU2010286532A8 (en) | Methods of treatment using anti-oxidized LDL antibodies | |
EA201591188A1 (ru) | Доставка глатирамера ацетата через слизистую оболочку | |
MX2015006970A (es) | Composiciones del virus del sindrome reproductor y respiratorio de porcino y sus usos. | |
MX347911B (es) | Vacuna contra virus de diarrea viral de bovinos. | |
WO2010045431A3 (en) | Dry powder formulations, vaccines and methods | |
MY172788A (en) | Influenza vaccines |